-
A U.S. congressman caused a stir in public health and sexually transmitted disease (STD) prevention circles in December by accusing federal health officials of failing to comply with federal law and asking them to testify at a special hearing.
-
-
The older I get, the more sentimental I become. I look at my own children and wonder if they will value my life-defining stories, or whether theyll simply suffer through them, as I have done with some of my parents own stories.
-
This is the first of a two-part series that looks at innovative approaches to patient care and expansion of services by home health agencies. This months article describes partnerships that are designed both to increase referral bases and enhance home health services.
-
Both vincristine and doxorubicin and their metabolites have been associated with allergic reactions when given to patients. The aerosolization of the drug present in the urine may have provided enough exposure for symptoms to develop.
-
Advances in Cardiovascular Technology: Emerging Markets for the 21st Century, Vol. 2, the newest sourcebook from the publishers of Cardiovascular Device Update and The BBI Newsletter, is now available.
-
For a medical disorder affecting more than a quarter-million Americans each year, said vascular surgeon Thomas Wakefield, we researchers dont know much more today about what causes blood clots in veins than our predecessors did over 100 years ago.
-
Describing the effort as a revolution in health and care information, the UK government last month announced a program intended to result in every National Health Service (NHS) patient in England having an electronic care record by the end of this decade. British Telecom (BT) was awarded a 10-year contract to set up and run the national NHS Care Records Service.
-
Bio-Imaging Technologies (Newtown, Pennsylvania) has acquired the intellectual property of privately held CapMed (Wilmington, Delaware), including the Personal Health Record (PHR) software and the patent-pending Personal HealthKey technology. Financial terms of the transaction were undisclosed.
-
An FDA advisory panel gave its unanimous backing to the second in what is likely to be a lengthening line of premarket approval (PMAs) applications for drug-eluting stents (DES). The nod went to the Taxus paclitaxel-eluting coronary stent from Boston Scientific (Natick, Massachusetts).
